AU2017211395B2 - Split inteins with exceptional splicing activity - Google Patents

Split inteins with exceptional splicing activity Download PDF

Info

Publication number
AU2017211395B2
AU2017211395B2 AU2017211395A AU2017211395A AU2017211395B2 AU 2017211395 B2 AU2017211395 B2 AU 2017211395B2 AU 2017211395 A AU2017211395 A AU 2017211395A AU 2017211395 A AU2017211395 A AU 2017211395A AU 2017211395 B2 AU2017211395 B2 AU 2017211395B2
Authority
AU
Australia
Prior art keywords
seq
fragment
intein
split intein
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017211395A
Other languages
English (en)
Other versions
AU2017211395A1 (en
Inventor
Tom W. Muir
Neel H. Shah
Adam J. Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Princeton University
Original Assignee
Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Princeton University filed Critical Princeton University
Publication of AU2017211395A1 publication Critical patent/AU2017211395A1/en
Application granted granted Critical
Publication of AU2017211395B2 publication Critical patent/AU2017211395B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AU2017211395A 2016-01-29 2017-01-27 Split inteins with exceptional splicing activity Active AU2017211395B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662288661P 2016-01-29 2016-01-29
US62/288,661 2016-01-29
PCT/US2017/015455 WO2017132580A2 (en) 2016-01-29 2017-01-27 Split inteins with exceptional splicing activity

Publications (2)

Publication Number Publication Date
AU2017211395A1 AU2017211395A1 (en) 2018-09-06
AU2017211395B2 true AU2017211395B2 (en) 2024-04-18

Family

ID=59398921

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017211395A Active AU2017211395B2 (en) 2016-01-29 2017-01-27 Split inteins with exceptional splicing activity

Country Status (14)

Country Link
US (2) US11142550B2 (https=)
EP (2) EP3408292B1 (https=)
JP (1) JP7290305B2 (https=)
CN (1) CN108884154A (https=)
AU (1) AU2017211395B2 (https=)
CA (1) CA3051195A1 (https=)
DK (1) DK3408292T3 (https=)
ES (1) ES2949163T3 (https=)
FI (1) FI3408292T3 (https=)
HU (1) HUE062276T2 (https=)
PL (1) PL3408292T3 (https=)
PT (1) PT3408292T (https=)
SI (1) SI3408292T1 (https=)
WO (1) WO2017132580A2 (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
AU2014255665B2 (en) 2013-04-18 2018-08-02 Fondazione Telethon Effective delivery of large genes by dual AAV vectors
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11319528B2 (en) 2015-07-13 2022-05-03 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
PT3408292T (pt) * 2016-01-29 2023-07-19 Univ Princeton Inteínas divididas com excecional atividade de splicing
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
CA3108281A1 (en) 2018-08-03 2020-02-06 Beam Therapeutics Inc. Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence
US11530245B2 (en) * 2018-08-31 2022-12-20 Washington University Split intein mediated polymerization and production of mussel foot adhesive protein materials
EP3847254A4 (en) 2018-09-07 2022-08-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
IL282362B2 (en) 2018-10-15 2025-10-01 Fond Telethon Ets Intein proteins and their uses
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
AU2020215730A1 (en) 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
LU101118B1 (en) * 2019-02-06 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Method for detecting a specific splice event of a gene of interest
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110714020B (zh) * 2019-05-22 2021-08-03 北京理工大学 一种高效简便纯化蛋白的方法
JP7759311B2 (ja) 2019-07-19 2025-10-23 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー リコンビナーゼ組成物及び使用方法
JP7579844B2 (ja) * 2019-08-28 2024-11-08 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティ 非定型スプリットインテインおよびそれらの使用
US20220332757A1 (en) * 2019-09-09 2022-10-20 Wuhan Yzy Biopharma Co., Ltd. Split intein and preparation method for recombinant polypeptide using the same
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
KR20220070481A (ko) * 2019-10-01 2022-05-31 유타대학연구재단 순환 종양 세포를 표적화하기 위한 혈소판 조작 방법
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
GB201917046D0 (en) * 2019-11-22 2020-01-08 Ge Healthcare Bioprocess R&D Ab Improved protein production
CN116209756A (zh) 2020-03-04 2023-06-02 旗舰先锋创新Vi有限责任公司 调控基因组的方法和组合物
CN111235174A (zh) * 2020-03-11 2020-06-05 梦芊科技知识产权有限公司 利用枯草芽孢杆菌和核酸内切酶制备人碱性成纤维细胞生长因子
EP3885440A1 (en) * 2020-03-26 2021-09-29 Splicebio, S.L. Split inteins and their uses
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
WO2021252975A2 (en) 2020-06-12 2021-12-16 Massachusetts Institute Of Technology Split intein-based selection for peptide binders
CA3196831A1 (en) 2020-09-25 2022-03-31 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
KR20240007210A (ko) * 2021-05-12 2024-01-16 씨티바 바이오프로세스 알＆디 에이비 개선된 단백질 정제
CN113735941B (zh) * 2021-08-13 2024-01-30 江南大学 一种蛋白纯化方法及其应用
KR102663243B1 (ko) * 2021-08-30 2024-05-03 국립순천대학교산학협력단 트립신 특이적 형광 프로브 및 이의 용도
AU2022343268A1 (en) 2021-09-08 2024-03-28 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
US20250353884A1 (en) * 2021-11-02 2025-11-20 Cornell University Intein systems and uses thereof
CN119630796A (zh) * 2022-05-26 2025-03-14 国立大学法人山形大学 异二聚体蛋白质的制造方法、二聚体蛋白质、单体蛋白质，以及靶标反应性异二聚体蛋白质的筛选方法
EP4594486A2 (en) * 2022-09-26 2025-08-06 Beam Therapeutics Inc. Synthetic polypeptides and uses thereof
EP4612166A1 (en) * 2022-11-01 2025-09-10 Memorial Sloan-Kettering Cancer Center Intein-based sorting system and modular chimeric polypeptides
WO2024170051A1 (en) * 2023-02-13 2024-08-22 Kutzner Christoph Fusion polypeptides for manufacturing of cyclic peptides
EP4724477A1 (en) 2023-06-11 2026-04-15 Regeneron Pharmaceuticals, Inc. Circularized antibody molecules
CN121909039A (zh) 2023-09-04 2026-04-21 斯普莱斯生物有限责任公司 分裂内含肽用于治疗scn1a相关疾病的用途
WO2025153705A1 (en) 2024-01-18 2025-07-24 Splicebio, Sl Use of split intein for the treatment of myo7a-associated disease
WO2025194124A1 (en) 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. Modified st1cas9 guide nucleic acids
WO2026013288A1 (en) 2024-07-12 2026-01-15 Splicebio, Sl Split intein for use in the treatment of cep290-associated disease
WO2026057767A1 (en) 2024-09-13 2026-03-19 Splicebio, Sl Use of split intein for the treatment of abca3-associated disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004336A2 (en) * 2012-06-27 2014-01-03 The Trustees Of Princeton University Split inteins, conjugates and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102096534B1 (ko) 2011-09-28 2020-04-03 에라 바이오테크, 에스.에이. 분할된 인테인 및 그의 이용
US10087213B2 (en) * 2013-01-11 2018-10-02 The Texas A&M University System Intein mediated purification of protein
PT3408292T (pt) * 2016-01-29 2023-07-19 Univ Princeton Inteínas divididas com excecional atividade de splicing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004336A2 (en) * 2012-06-27 2014-01-03 The Trustees Of Princeton University Split inteins, conjugates and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Shah et al., Ultrafast Protein Splicing is Common among Cyanobacterial Split Inteins: Implications for Protein Engineering, Journal of the American Chemical Society, vol. 134:11338-11341, and Supp. pp. S2-S52 (Jun. 26, 2012) (Year: 2012). *

Also Published As

Publication number Publication date
HUE062276T2 (hu) 2023-10-28
WO2017132580A3 (en) 2017-09-14
FI3408292T3 (fi) 2023-06-30
US12297472B2 (en) 2025-05-13
EP4234689A3 (en) 2023-09-13
AU2017211395A1 (en) 2018-09-06
JP2019506163A (ja) 2019-03-07
PL3408292T3 (pl) 2023-10-02
WO2017132580A2 (en) 2017-08-03
US11142550B2 (en) 2021-10-12
EP3408292A2 (en) 2018-12-05
SI3408292T1 (sl) 2023-09-29
CA3051195A1 (en) 2017-08-03
US20200055900A1 (en) 2020-02-20
US20210371467A1 (en) 2021-12-02
CN108884154A (zh) 2018-11-23
EP4234689A2 (en) 2023-08-30
DK3408292T3 (da) 2023-06-12
ES2949163T3 (es) 2023-09-26
JP7290305B2 (ja) 2023-06-13
EP3408292B1 (en) 2023-04-26
PT3408292T (pt) 2023-07-19
EP3408292A4 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
US12297472B2 (en) Split inteins with exceptional splicing activity
JP6591511B2 (ja) スプリットインテイン、複合体およびそれらの使用
Johnson et al. Towards the total chemical synthesis of integral membrane proteins: a general method for the synthesis of hydrophobic peptide-αthioester building blocks
Getz et al. Protease-resistant peptide ligands from a knottin scaffold library
AU605291B2 (en) Process for the purification of recombinant polypeptides
EP2075336B1 (en) Purification of recombinant proteins fused to multiple epitopes
Airenne et al. Recombinant avidin and avidin–fusion proteins
Cheng et al. Enzymatic on-resin peptide cleavage and in situ cyclization one-pot strategy for the synthesis of cyclopeptide and cyclotide
US10000544B2 (en) Process for production of insulin and insulin analogues
Tran et al. Evaluation of efficient non-reducing enzymatic and chemical ligation strategies for complex disulfide-rich peptides
EP3530674B1 (en) Polypeptide monomer, associated product formed of said polypeptide monomer having cell penetration function, norovirus component vaccine for subcutaneous, intradermal, percutaneous or intramuscular administration and having said associated product as effective component thereof, and method for producing said associated product
HK40098890A (en) Split inteins with exceptional splicing activity
CN117801123B (zh) 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法
HK40001246A (en) Split inteins with exceptional splicing activity
HK40001246B (en) Split inteins with exceptional splicing activity
Hwang et al. Bioproduction platform to generate functionalized disulfide-constrained peptide analogues
CN114685679A (zh) 谍捕手突变体及其制备方法与其在荧光蛋白质体系中的应用
Stevens et al. Supporting Information for: Design of a Split Intein with Exceptional Protein Splicing Activity
Bjerke Exploration of Protein Engineering Methods towards Biomaterials, Therapeutic Protein Scaffolds, and Localization Detection within Mammalian Cells
CN112259166A (zh) 一种靶向prss3的多肽类抑制剂的设计方法、多肽类抑制剂及其制备方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)